Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Clinical trial NCT03896984 · COMPLETED

Trial details

NCT number: NCT03896984
Sponsor: Bayer
Status: COMPLETED
Study type: OBSERVATIONAL

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start date: 2019-03-18
Primary completion: 2020-06-08
Enrollment: 346

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.